Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Deals

Hainan Haiyao and Elken Global Form Five-Year Strategic Partnership in Wellness Products

Fineline Cube May 16, 2025

China-based Hainan Haiyao Co., Ltd. (SHE: 000566) has entered into a five-year strategic collaboration agreement...

Company Medical Device

Beijing Balance Medical’s Renato System Gets NMPA Approval for Valve-in-Valve Therapy

Fineline Cube May 16, 2025

China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has obtained market authorization from China’s...

Company Drug

North China Pharma Wins NMPA Approval for Clinical Trials of Recombinant Tetanus Vaccine

Fineline Cube May 16, 2025

China-based North China Pharmaceutical Group Corporation (SHA: 600812) announced that it has received clinical trial...

Company Deals

Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss

Fineline Cube May 16, 2025

South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration...

Company

Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth

Fineline Cube May 16, 2025

Merck KGaA (ETR: MRK) released its Q1 2025 financial results, reporting a 2.5% year-on-year (YOY)...

Company Drug

CanSino Biologics Gets Indonesian Approval for Phase I Trial of Inhalable Tuberculosis Vaccine

Fineline Cube May 16, 2025

China-based CanSino Biologics Inc. (HKG: 6185), a specialist in vaccine development, has announced that it...

Company Drug

Haisco Pharma’s HSK21542 Approved by NMPA for Post-Abdominal Surgery Pain

Fineline Cube May 16, 2025

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval...

Company Medical Device

Lifetech Scientific’s Aortic Arch Stent System Approved by China’s NMPA

Fineline Cube May 16, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received marketing approval from...

Company Drug

Sihuan Pharmaceutical’s Bireociclib Approved by NMPA for Advanced Breast Cancer

Fineline Cube May 16, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...

Company Drug

CANbridge’s Velaglucerase β Approved by NMPA for Gaucher’s Disease Long-Term Therapy

Fineline Cube May 16, 2025

China-based CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the National Medical Products Administration (NMPA) has...

Company Deals

Merck KGaA and JD Health Launch Online Thyroid Care Center in China

Fineline Cube May 16, 2025

The Thyroid Care Center on the JD Health platform, a joint initiative between German pharmaceutical...

Company Drug

Novartis’ Scemblix Approved by NMPA for Newly Diagnosed Ph+ CML-CP Patients

Fineline Cube May 15, 2025

Swiss pharmaceutical company Novartis (NYSE: NVS) announced that it has received marketing approval from China’s...

Company Drug

AbbVie’s Emrelis Granted FDA Accelerated Approval for NSCLC with High c-MET Overexpression

Fineline Cube May 15, 2025

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to AbbVie’s (NYSE: ABBV)...

Company

BeiGene Announces Plans to Relocate Headquarters to Switzerland from Cayman Islands

Fineline Cube May 15, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology company that has proposed...

Company Drug

Chengdu Kanghong’s KH607 Approved for Clinical Trials in Postpartum Depression

Fineline Cube May 15, 2025

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) has announced that it has received...

Medical Device Policy / Regulatory

NMPA Releases Updated List of Medical Devices Exempted from Clinical Evaluation

Fineline Cube May 15, 2025

The National Medical Products Administration (NMPA) has released the latest version of the “List of...

Company Drug

Boehringer Ingelheim’s Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis

Fineline Cube May 15, 2025

Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products...

Company Drug

Novartis’ Kisqali Receives NMPA Approval for High-Risk Early Breast Cancer

Fineline Cube May 15, 2025

Switzerland-based Novartis (NYSE: NVS) announced this week that it has received another indication approval from...

Company Deals

MGI Tech Partners with Genoks to Enhance Clinical Testing Services in Türkiye

Fineline Cube May 15, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd. (SHA: 688114) has entered into a strategic...

Company Deals

Jiangsu Hengrui Pharmaceuticals Launches Hong Kong IPO of H-Shares

Fineline Cube May 15, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has officially launched an initial public offering...

Posts pagination

1 … 161 162 163 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.